Targeted drug delivery market set to surge as biologics outpace traditional drugs

In Dublin, a report was released on April 9, 2025, highlighting future trends and forecasts in the targeted drug delivery device market. The market is expected to rapidly grow, particularly with advancements in the fields of cell biology and pharmacology that are contributing to a shift towards biologics from traditional drugs. The report indicates significant segmentation in the market based on device types, therapeutic areas, and routes of administration, with catheters and cannulas being key device types. According to the research, targeted drug delivery devices for the brain are projected to experience growth at a relatively faster pace. This growth is fueled by the potential effectiveness of direct biologic delivery systems catering to oncological conditions and other critical disorders. Notably, the intratumoral administration route is anticipated to dominate the market due to its capacity to minimize the systemic side effects of drugs while maximizing their localized therapeutic impact. Additionally, the study illustrates that over 30% of the devices are aimed at the brain, followed closely by devices targeting the heart. The prevalence of trials focused on Gene and Stem Cell therapies indicates a robust interest from the medical community in combining these therapies with targeted delivery systems. Insights were gathered from various industry stakeholders, presenting a comprehensive overview of the factors likely to shape the market's evolution in the years to come. Furthermore, the analysis forecasts strong market performance, especially in North America and Europe, which are poised to capture the majority market share. The data underlines an expectation that within the next decade, significant innovations in the targeted delivery landscape will lead to enhanced patient outcomes, particularly in the treatment of cancer and cardiovascular disorders, emphasizing the importance of continued research and development in this field.